Lonza to Supply Stem Cell Therapy Drug to Maryland Biotech Firm

Lonza says it has secured a deal with biotech firm Osiris Therapeutics (Columbia, MD) to manufacture what it says could be the world’s first stem cell drug. The agreement calls for Lonza to manufacture Osiris’s Prochymal stem cell therapy, which is being evaluated in phase III clinical trials for three medical applications including Crohn’s disease. Lonza says it will invest “millions of dollars” to build a Prochymal facility at its Walkersville, MD site. Financial terms were not disclosed. von Hippel: A focus on profitable products...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers